Vasileiadis Ioannis E, Goudis Christos A, Giannakopoulou Pinelopi T, Liu Tong
a Department of Cardiology , General Hospital of Thessaloniki G. Papanikolaou , Thessaloniki , Greece.
b Department of Cardiology , General Hospital of Serres , Serres , Greece.
COPD. 2018 Apr;15(2):148-156. doi: 10.1080/15412555.2018.1432034. Epub 2018 Mar 9.
Chronic obstructive pulmonary disease (COPD) is a complex disorder that primarily affects the lungs and is characterized not only by local pulmonary, but also by systemic inflammation which promotes the development of extrapulmonary and cardiovascular co-morbidities. Angiotensin converting enzyme (ACE) inhibitors and ARBs (angiotensin receptor blockers) are widely used drugs in the treatment of cardiovascular diseases, with growing evidence suggesting potential benefits in COPD patients. The purpose of this review is to describe the correlation of renin-angiotensin system (RAS) with COPD pathophysiology and to present the latest data regarding the potential role of RAS blockers in COPD.
慢性阻塞性肺疾病（COPD）是一种主要影响肺部的复杂疾病，其特征不仅在于局部肺部炎症，还在于全身性炎症，这种全身性炎症会促进肺外和心血管合并症的发展。血管紧张素转换酶（ACE）抑制剂和血管紧张素受体阻滞剂（ARB）是治疗心血管疾病的常用药物，越来越多的证据表明它们对COPD患者可能有益。本综述的目的是描述肾素-血管紧张素系统（RAS）与COPD病理生理学的相关性，并介绍有关RAS阻滞剂在COPD中潜在作用的最新数据。
